Riedinger JM - Search Results

1

[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles].

Riedinger JM, Eche N, Basuyau JP, Daver A, Touzery C, Mayer F, Coudert B, Fargeot P, Chauffert B, de Gislain C, Zanetta S. Riedinger JM, et al. Ann Biol Clin (Paris). 2002 Mar-Apr;60(2):183-91. Ann Biol Clin (Paris). 2002. PMID: 11937443 Free article. French.

2

Fourier and factorial analysis: an objective and comparative evaluation on a cardiac phantom.

Kotzki PO, Touzery C, Munsch T, Riedinger JM, Gogou L, Piffaut P, Bidan Y, Pelletier JL. Kotzki PO, et al. Among authors: riedinger jm. Eur J Nucl Med. 1987;13(9):450-5. doi: 10.1007/BF00281859. Eur J Nucl Med. 1987. PMID: 3440470

3

Normal range of [99mTc]MAG-3 renogram parameters in renal transplant recipients.

Riedinger-Berriolo A, Touzery C, Chevet D, Toubeau M, Riedinger JM, Mezeray C, Brunotte F. Riedinger-Berriolo A, et al. Among authors: riedinger jm. Transplant Proc. 1994 Feb;26(1):301-2. Transplant Proc. 1994. PMID: 8108994 No abstract available.

4

[Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].

Riedinger JM, Barillot I, Coudert B, Fargeot P, Berriolo-Riedinger A, Guerrin J. Riedinger JM, et al. Bull Cancer. 1996 Aug;83(8):654-63. Bull Cancer. 1996. PMID: 8869046 French.

5

[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].

Coudert B, De Gislain C, Beltramo JL, Guigues B, Mayer F, Bruchon Y, Riedinger JM, Fargeot P, Dumas M, Guerrin J. Coudert B, et al. Among authors: riedinger jm. Bull Cancer. 1996 Oct;83(10):847-52. Bull Cancer. 1996. PMID: 8952635 French.

6

[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].

Riedinger JM, Coudert B, Barillot I, Buffenoir G, Mayer F, Fargeot P, Cuisenier J, Guerrin J. Riedinger JM, et al. Bull Cancer. 1997 Sep;84(9):855-60. Bull Cancer. 1997. PMID: 9435806 French.

7

MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.

Lizard-Nacol S, Genne P, Coudert B, Riedinger JM, Arnal M, Sancy C, Brunet-Lecomte P, Fargeot P. Lizard-Nacol S, et al. Among authors: riedinger jm. Anticancer Res. 1999 Jul-Aug;19(4C):3575-81. Anticancer Res. 1999. PMID: 10629655

8

Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer.

Arnal M, Franco N, Fargeot P, Riedinger JM, Brunet-Lecomte P, Lizard-Nacol S. Arnal M, et al. Among authors: riedinger jm. Breast Cancer Res Treat. 2000 May;61(1):13-20. doi: 10.1023/a:1006449931921. Breast Cancer Res Treat. 2000. PMID: 10930086

9

Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer.

Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, Fargeot P, Brunet-Lecomte P. Lizard-Nacol S, et al. Among authors: riedinger jm. Breast Cancer Res. 1999;1(1):81-7. doi: 10.1186/bcr17. Epub 1999 Sep 1. Breast Cancer Res. 1999. PMID: 11056682 Free PMC article.

10

[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].

Basuyau JP, Blanc-Vincent MP, Bidart JM, Daver A, Deneux L, Eche N, Gory-Delabaere G, Pichon MF, Riedinger JM. Basuyau JP, et al. Among authors: riedinger jm. Bull Cancer. 2000 Oct;87(10):723-37. Bull Cancer. 2000. PMID: 11084536 Free article. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters